174 related articles for article (PubMed ID: 33902692)
61. Neuroinflammation Preceding and Accompanying Primary Central Nervous System Lymphoma: Case Study and Literature Review.
Lu JQ; O'Kelly C; Girgis S; Emery D; Power C; Blevins G
World Neurosurg; 2016 Apr; 88():692.e1-692.e8. PubMed ID: 26724610
[TBL] [Abstract][Full Text] [Related]
62. Current status and future of relapsed primary central nervous system lymphoma (PCNSL).
Tyson RM; Siegal T; Doolittle ND; Lacy C; Kraemer DF; Neutwelt EA
Leuk Lymphoma; 2003 Apr; 44(4):627-33. PubMed ID: 12769339
[TBL] [Abstract][Full Text] [Related]
63. [Case of 55-year-old female with primary central nervous system lymphoma, presenting with brain and eye lesions and long-term relapsing/remitting course].
Sasaki T; Nakayama T; Kitamura M; Kakuta Y; Imafuku I
Rinsho Shinkeigaku; 2015; 55(8):567-72. PubMed ID: 26156255
[TBL] [Abstract][Full Text] [Related]
64. A review of a novel, Bruton's tyrosine kinase inhibitor, ibrutinib.
Lee CS; Rattu MA; Kim SS
J Oncol Pharm Pract; 2016 Feb; 22(1):92-104. PubMed ID: 25425007
[TBL] [Abstract][Full Text] [Related]
65. Allogeneic stem cell transplantation for relapsed primary central nervous system lymphoma: Is it feasible?
Atilla E; Sahin U; Atilla PA; Merter M; Ozyurek E; Ceyhan K; Bozdag SC
Hematol Oncol Stem Cell Ther; 2019 Dec; 12(4):220-225. PubMed ID: 29559300
[TBL] [Abstract][Full Text] [Related]
66. Unusual relapse of primary central nervous system lymphoma.
Igala M
Springerplus; 2016; 5():301. PubMed ID: 27066337
[TBL] [Abstract][Full Text] [Related]
67. Recovery from coma of a patient having acute progression of primary central nervous system lymphoma using tirabrutinib and methylprednisolone.
Satow T; Horiguchi S; Komuro T
Neurooncol Adv; 2020; 2(1):vdaa164. PubMed ID: 33409497
[No Abstract] [Full Text] [Related]
68. High-dose chemotherapy with autologous haematopoietic stem cell support for relapsed or refractory primary CNS lymphoma: a prospective multicentre trial by the German Cooperative PCNSL study group.
Kasenda B; Ihorst G; Schroers R; Korfel A; Schmidt-Wolf I; Egerer G; von Baumgarten L; Röth A; Bloehdorn J; Möhle R; Binder M; Keller U; Lamprecht M; Pfreundschuh M; Valk E; Fricker H; Schorb E; Fritsch K; Finke J; Illerhaus G
Leukemia; 2017 Dec; 31(12):2623-2629. PubMed ID: 28559537
[TBL] [Abstract][Full Text] [Related]
69. Acalabrutinib, A Second-Generation Bruton's Tyrosine Kinase Inhibitor.
Kriegsmann K; Kriegsmann M; Witzens-Harig M
Recent Results Cancer Res; 2018; 212():285-294. PubMed ID: 30069636
[TBL] [Abstract][Full Text] [Related]
70. Recent Progress on Primary Central Nervous System Lymphoma-From Bench to Bedside.
Shao L; Xu C; Wu H; Jamal M; Pan S; Li S; Chen F; Yu D; Liu K; Wei Y
Front Oncol; 2021; 11():689843. PubMed ID: 34485125
[TBL] [Abstract][Full Text] [Related]
71. Pilot trial of ibrutinib in patients with relapsed or refractory T-cell lymphoma.
Kumar A; Vardhana S; Moskowitz AJ; Porcu P; Dogan A; Dubovsky JA; Matasar MJ; Zhang Z; Younes A; Horwitz SM
Blood Adv; 2018 Apr; 2(8):871-876. PubMed ID: 29669753
[TBL] [Abstract][Full Text] [Related]
72. Targeting BTK in CLL: Beyond Ibrutinib.
Bond DA; Woyach JA
Curr Hematol Malig Rep; 2019 Jun; 14(3):197-205. PubMed ID: 31028669
[TBL] [Abstract][Full Text] [Related]
73. Salvage chemoimmunotherapy with rituximab, ifosfamide and etoposide (R-IE regimen) in patients with primary CNS lymphoma relapsed or refractory to high-dose methotrexate-based chemotherapy.
Mappa S; Marturano E; Licata G; Frezzato M; Frungillo N; Ilariucci F; Stelitano C; Ferrari A; Sorarù M; Vianello F; Baldini L; Proserpio I; Foppoli M; Assanelli A; Reni M; Caligaris-Cappio F; Ferreri AJ
Hematol Oncol; 2013 Sep; 31(3):143-50. PubMed ID: 23161567
[TBL] [Abstract][Full Text] [Related]
74. Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study.
Younes A; Thieblemont C; Morschhauser F; Flinn I; Friedberg JW; Amorim S; Hivert B; Westin J; Vermeulen J; Bandyopadhyay N; de Vries R; Balasubramanian S; Hellemans P; Smit JW; Fourneau N; Oki Y
Lancet Oncol; 2014 Aug; 15(9):1019-26. PubMed ID: 25042202
[TBL] [Abstract][Full Text] [Related]
75. Using the drug repositioning approach to develop a novel therapy, tipepidine hibenzate sustained-release tablet (TS-141), for children and adolescents with attention-deficit/hyperactivity disorder.
Saito T; Yamashita Y; Tomoda A; Okada T; Umeuchi H; Iwamori S; Shinoda S; Mizuno-Yasuhira A; Urano H; Nishino I; Saito K
BMC Psychiatry; 2020 Nov; 20(1):530. PubMed ID: 33167920
[TBL] [Abstract][Full Text] [Related]
76. Imaging features (CT, MRI, MRS, and PET/CT) of primary central nervous system lymphoma in immunocompetent patients.
Cheng G; Zhang J
Neurol Sci; 2019 Mar; 40(3):535-542. PubMed ID: 30580380
[TBL] [Abstract][Full Text] [Related]
77. Stereotactic Brachytherapy with Iodine-125 Seeds Plus Temozolomide Induced Complete and Durable Remission in a Patient with Recurrent Primary Central Nervous System Lymphoma.
Zheng J; Wang C; Liu F
World Neurosurg; 2018 Sep; 117():316-320. PubMed ID: 29960094
[TBL] [Abstract][Full Text] [Related]
78. [An autopsy case of primary central nervous system lymphoma with diffuse intracerebral lesion].
Kazahaya Y; Doi A; Hamaya K
No To Shinkei; 1992 Jan; 44(1):65-70. PubMed ID: 1562388
[TBL] [Abstract][Full Text] [Related]
79. Advances in the therapy of primary central nervous system lymphoma.
Plotkin SR; Batchelor TT
Clin Lymphoma; 2001 Mar; 1(4):263-75; discussion 276-7. PubMed ID: 11707839
[TBL] [Abstract][Full Text] [Related]
80. Primary CNS lymphoma at first relapse/progression: characteristics, management, and outcome of 256 patients from the French LOC network.
Langner-Lemercier S; Houillier C; Soussain C; Ghesquières H; Chinot O; Taillandier L; Soubeyran P; Lamy T; Morschhauser F; Benouaich-Amiel A; Ahle G; Moles-Moreau MP; Moluçon-Chabrot C; Bourquard P; Damaj G; Jardin F; Larrieu D; Gyan E; Gressin R; Jaccard A; Choquet S; Brion A; Casasnovas O; Colin P; Reman O; Tempescul A; Marolleau JP; Fabbro M; Naudet F; Hoang-Xuan K; Houot R
Neuro Oncol; 2016 Sep; 18(9):1297-303. PubMed ID: 26951382
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
